Oremek G M, Eigenbrodt E, Rädle J, Zeuzem S, Seiffert U B
University Hospital, Central Laboratory, Frankfurt/Main, Germany.
Anticancer Res. 1997 Jul-Aug;17(4B):3031-3.
The monoclonal antibody pyruvate kinase type tumor M2 (TUM2-PK) has been shown to have a high binding capacity to pancreatic cancer. In present study TUM2-PK serum levels were measured in pancreatic cancer and compared with the reference tumor markers CA19-9, CA50, CA72-4 and CEA. Overall 100 patients were included in this study, 64 patients had a histologically confirmed pancreatic carcinoma, 36 patients gastrointestinal cancer (stomach, colon), 666 healthy volunteers served as controls. Measurements were done by enzymimmunoassay. For the healthy blood donors a cut-off value of 22.5 U/ml was evaluated, which corresponds to 95% specificity. In patients with pancreatic cancer the sensitivities of TUM2-PK, CA19-9, CEA, CA72-4 and CA50 were 71%; 68%, 37%, 49% and 63.4% respectively. Linear regression analysis indicated that there was a positive correlation (r = 0.79). According to the results of our study TUM2-PK has comparable sensitivity but higher specificity than the reference tumor marker CA19-9.
单克隆抗体丙酮酸激酶M2型肿瘤（TUM2 - PK）已被证明对胰腺癌具有高结合能力。在本研究中，对胰腺癌患者的TUM2 - PK血清水平进行了测量，并与参考肿瘤标志物CA19 - 9、CA50、CA72 - 4和CEA进行了比较。本研究共纳入100例患者，其中64例经组织学确诊为胰腺癌，36例为胃肠道癌（胃癌、结肠癌），666名健康志愿者作为对照。测量采用酶免疫分析法。对于健康献血者，评估的临界值为22.5 U/ml，其对应95%的特异性。在胰腺癌患者中，TUM2 - PK、CA19 - 9、CEA、CA72 - 4和CA50的敏感性分别为71%、68%、37%、49%和63.4%。线性回归分析表明存在正相关（r = 0.79）。根据我们的研究结果，TUM2 - PK具有与参考肿瘤标志物CA19 - 9相当的敏感性，但特异性更高。
